Arrowhead Pharmaceuticals vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Arrowhead Pharmaceuticals Inc (ARWR)

Q3 202622 Jun – 30 Aug 2026

▲3

Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins

EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.

July 202622 Jun – 30 Aug 2026

▲3

Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins

EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.

Latest22 Jun – 30 Aug 2026

▲3

Arrowhead's RNAi pipeline advances with EU launch and Phase 3 wins

EU approval of REDEMPLO opens first market Arrowhead won European Commission approval for REDEMPLO, the first siRNA treatment for familial chylomicronemia syndrome. This opens a new revenue stream and validates its RNAi platform, lifting investor expectations for future drug approvals and sales.
First regulatory approval in a major market is a key catalyst for ARWR's commercial future.
Plozasiran Phase 3 success pressures rival Ionis Plozasiran met all endpoints in two Phase 3 trials for severe hypertriglyceridemia, cutting triglycerides by ~80% and pancreatitis events by 78%. This positions ARWR ahead of Ionis's competing drug, boosting confidence in a large market opportunity.
Late-stage win with best-in-class potential directly boosts ARWR's competitive position and future sales outlook.
Zodasiran enrollment complete for HoFH Arrowhead finished enrolling 70 patients in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, ahead of schedule. This keeps another pipeline drug on track for a 2027 readout, adding long-term value.
Pipeline progress reduces reliance on a single drug and supports future growth.
Q3 loss widens but revenue beats and cash remains strong Arrowhead reported a $194 million quarterly loss and spent $215 million on a priority review voucher, but revenue jumped 171% to $75 million and cash stands at $1.6 billion. The voucher could speed FDA review of plozasiran, while the loss highlights heavy spending.
Financials show both growing commercial traction and ongoing cash burn, a key tension for investors.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.